membranous nephropathy
Conditions
Interventions
Index test:PLA2R antibody, THSD7A antibody, and C1q antibody are detected in serum using magnetic particle chemiluminescence immunoassay.
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Gender: No restriction, both male and female patients are eligible for enrollment. It is recommended that the proportion of females be no less than 30% (the male-to-female ratio in membranous nephropathy is approximately 2:1). Postmenopausal women should be specifically indicated (due to the influence of hormones on immune status). 2. Age: It is recommended to include patients aged 18–75 years (primarily adult patients to avoid the influence of physiological differences in children or the elderly on antibody levels). 3. Healthy Control Group: Age- and gender-matched completely healthy individuals from a physical examination population, with no history of kidney disease (glomerular filtration rate >=90 mL/min/1.73m², negative for urinary protein) or family history of autoimmune diseases. 4. Membranous Nephropathy Group: Patients diagnosed with membranous nephropathy, with idiopathic membranous nephropathy classified into stages I–IV according to the Ehrenreich-Churg staging system. Patients pathologically confirmed to have atypical membranous nephropathy should be actively investigated for secondary causes. Those who are informed about the study and have signed the consent form are included. The presence of proteinuria is required.
Exclusion criteria
Exclusion criteria: 1. Patients with diabetes, obesity, malignant tumors, acute kidney disease, severe comorbidities (such as severe infections, cardiovascular, hepatic, hematopoietic, or neuropsychiatric system diseases), pregnant or lactating women, and patients with mental disorders or cognitive dysfunction. 2. Use of rituximab or other B-cell-depleting agents that may affect antibody testing within the past 3 months. 3. Use of high-dose corticosteroid therapy. 4. Vaccination within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| THSD7A antibody;PLA2R antibody;Negative Predictive Value;Sensitivity;Area Under the ROC Curve;Specificity;Youden's Index;Accuracy;Prevalence;Positive Predictive Value; | — |
Secondary
| Measure | Time frame |
|---|---|
| C1q antibody; | — |
Countries
China
Contacts
Public ContactGuan Ming
Huashan Hospital, Fudan University
Outcome results
None listed